Kenya’s plan to establish a regional pharmaceutical manufacturing hub has received a boost after Sweden’s development finance institution, Swedfund, committed funding to support preparatory studies for the proposed Biopharma Life Sciences Park at Konza Technopolis.
The project, which will be developed through a public-private partnership (PPP) between Apifa Biotech and the Technopolis Development Authority (TDA), received approval from the National Treasury in April 2026 to proceed to the development phase.
The proposed facility aims to strengthen local production of medicines and medical supplies, reduce reliance on imports and position Kenya as a key player in the regional pharmaceutical manufacturing industry.
A consortium comprising global real estate and investment advisory firm Jones Lang LaSalle (JLL) and healthcare research and analytics company IQVIA has been selected to undertake the feasibility study.
The two firms will provide expertise in life sciences strategy, infrastructure development, investment advisory and operational planning to guide the proposed project.
TDA Chief Executive Officer John Paul Okwiri said the park would help position Konza as a centre for pharmaceutical manufacturing, biotechnology innovation and investment.
“The Biopharma Life Sciences Park will position Konza as an emerging centre for life sciences and pharmaceutical manufacturing, helping Kenya move from importing most of its medicines to producing them locally,” said Okwiri.
He said the project also demonstrated the role of public-private partnerships in mobilising expertise, financing and technical capacity to deliver major infrastructure projects.
“Konza Technopolis is a strong champion of public-private partnerships because we believe they are the most practical way to move huge infrastructure from paper to reality. This project is a clear example of why private expertise and capital mobilisation matter,” he added.
Swedfund’s grant will finance technical and commercial assessments to establish the project’s feasibility, strengthen its investment case and prepare it for subsequent development phases.
Elsa Ekblom, Health Sector Lead at Swedfund’s Project Accelerator, said the support would help lay the groundwork for the project and attract long-term private investment.
“This funding commitment we are making today will help to advance the necessary groundwork, strengthen project preparation, and create a clear pathway toward maximising national development outcomes and attracting long-term private investment to develop Kenya’s pharmaceutical and life sciences sector,” she said.
Apifa Biotech Board Chairman Dr Gerald Macharia and Chief Executive Officer Dr Keter witnessed the signing ceremony and reaffirmed the company’s commitment to the project.
Dr Keter said the partnership with Konza, Swedfund’s financial support and the appointment of JLL and IQVIA marked an important milestone towards establishing a pharmaceutical manufacturing hub serving Kenya and the East African Community.
The proposed park, which will be designed, developed and financed by Apifa Biotech, is expected to bring together pharmaceutical manufacturers, researchers, investors and technology companies.
The initiative also supports Konza Technopolis’ ambition to become a centre for technology, research and industrial development.
It is aligned with the African Union’s target of meeting 60 per cent of Africa’s health product needs through local manufacturing by 2040, as well as Kenya’s plans to increase domestic production of essential health products.
The feasibility study is expected to establish the project’s technical requirements, commercial viability, investment structure and implementation roadmap, paving the way for the next stage of development.

